This article is the regulatory deep dive on Health Canada's Special Access Program (SAP) for psilocybin — written for physicians, nurse practitioners, clinicians, and patients who want to understand the regulatory framework in detail rather than the patient-friendly access version. (For the patient-friendly version, see How to Access Psilocybin Therapy in Canada.) The pathway has three regulatory eras: the pre-2022 Section 56(1) exemption framework that produced the August 2020 first cohort of four terminally ill Canadian patients; the January 5, 2022 SAP amendment that created the durable practitioner-initiated pathway operating today; and the 2025 access tightening reported by PsyCan as approval rates declined under the current government. Beyond the regulatory framework itself, this article covers the practical SAP application from a physician's perspective, the drug supply chain (Filament, Optimi, Psyence, Compass), constitutional challenges (Tobin, Toth v. Canada Federal Court work), and what would change if Compass Pathways' Phase 3 program produces a Notice of Compliance from Health Canada in the coming years.

Key takeaways

Three regulatory eras: Section 56(1) exemptions (pre-2022; first 4 patients August 2020); the January 5, 2022 SAP amendment (the durable pathway); and the 2025 access tightening (PsyCan-reported sharp decline in approvals).

The January 5, 2022 amendment repealed restrictions in the Food and Drug Regulations that had previously excluded restricted drugs from SAP since 2013, restoring practitioner-initiated SAP access for psilocybin and MDMA.

SAP applications are physician- or NP-initiated for individual patients with serious or life-threatening conditions where conventional treatments have failed, are unsuitable, or are unavailable. Patients cannot apply directly.

Statistics (per PsyCan and TheraPsil reporting): cumulative ~301 psilocybin SAP authorizations since January 2022 by mid-2025; year-by-year approval rates declined sharply through 2025; review timelines lengthened.

Drug supply is from Health Canada-licensed Canadian producers: Filament Health (often provides drug at no charge to SAP patients), Optimi Health, Psyence Group; some imported Compass Pathways COMP360.

Constitutional and Federal Court challenges including Tobin v. Canada and Toth v. Canada Federal Court work continue to address access barriers for patients and training-pathway exemptions for practitioners.

A future Notice of Compliance for psilocybin (likely earliest from Compass Pathways' Phase 3 program if it succeeds) would change the regulatory architecture from SAP-only to approved-indication, transforming Canadian access.

The pre-2022 era — Section 56(1) and the first four patients

Before the January 2022 amendment, psilocybin access in Canada required Section 56(1) exemptions under the Controlled Drugs and Substances Act (CDSA). Section 56(1) gives the Minister of Health discretionary authority to exempt persons or controlled substances from the application of the Act for a "medical or scientific purpose or in the public interest." It was rarely granted for therapeutic psychedelic use in the decades following psilocybin's CDSA scheduling.

August 4, 2020 — the first four

Health Canada granted Section 56(1) exemptions to four terminally ill Canadians for psilocybin-assisted therapy for end-of-life distress. The exemptions were the result of years of advocacy led by TheraPsil, founded by Dr. Bruce Tobin and Spencer Hawkswell. The four cases established proof-of-concept for the regulatory framework that would eventually become the SAP amendment.

December 2020 — practitioner training exemptions

Health Canada granted Section 56(1) exemptions to 19 healthcare professionals for experiential training in psilocybin-assisted therapy. This established a parallel regulatory track for clinician training that would later become contested in the Toth v. Canada Federal Court case.

Continued case-by-case exemptions through 2021

Individual Section 56 exemptions continued to be granted on a case-by-case basis through 2021, but the framework was capacity-limited and arbitrary — each exemption required ministerial-level review, lacked predictable timelines, and was not a sustainable regulatory architecture for the growing demand.

January 5, 2022 — the SAP amendment

Health Canada amended the Food and Drug Regulations (published in Canada Gazette Part II) to repeal restrictions that had excluded restricted drugs from the Special Access Program since 2013. The practical effect: physicians and nurse practitioners could now request psilocybin (and MDMA) through the SAP pathway for individual patients with serious or life-threatening conditions where conventional treatments have failed, were unsuitable, or were unavailable.

The official notice is at Requests to the Special Access Program (SAP) involving psychedelic-assisted psychotherapy.

Key regulatory features of the post-2022 SAP framework

Practitioner-initiated: a licensed physician or nurse practitioner submits the SAP request on behalf of an individual patient. Patients cannot apply directly.
Case-specific: each request is for one patient, one course of treatment. There is no class authorization for multiple patients or for ongoing maintenance therapy beyond the authorized course.
Eligible conditions: "serious or life-threatening" conditions where conventional treatments have failed, are unsuitable, or are unavailable. In practice: end-of-life distress (most common), TRD, AUD, demoralization, cluster headache, and others case-by-case.
Documentation requirements: the prescribing practitioner must document conventional treatment failures, justify the choice of psilocybin with reference to peer-reviewed evidence, identify a Canadian licensed drug supplier, and submit the eight-page SAP request form.
Class exemptions: Health Canada has issued class exemptions under Section 56 for practitioners conducting SAP-authorized psilocybin/MDMA activities, allowing storage, transport, and administration consistent with the SAP authorization.

First authorization under the new framework

March 21, 2022: Dr. Valorie Masuda (BC palliative-care physician) was granted the first SAP psilocybin authorization under the new framework, for six end-of-life patients.

The SAP application — physician's perspective

The eight-page Health Canada SAP request form structures the application. From a prescribing physician's perspective:

Section 1 — Patient details

Patient identifiers (within privacy-appropriate handling)
Diagnosis and clinical history
Documented serious or life-threatening condition

Section 2 — Justification

Conventional treatments tried, at what dose, for what duration, with what response
Why conventional treatments have failed, are unsuitable, or are unavailable
Reference to peer-reviewed evidence supporting psilocybin for the indication (Griffiths 2016, Davis 2021, Goodwin 2022, Bogenschutz 2022, Anderson 2020 are the most-cited foundations)

Section 3 — Treatment plan

Specific protocol: drug, dose, schedule, administration setting, supervising clinicians
Preparation and integration plan
Safety screening and contraindication clearance

Section 4 — Drug source

Identification of a Canadian Health Canada-licensed psilocybin supplier (Filament Health, Optimi Health, Psyence Group, or imported Compass COMP360 with import authorization)

Section 5 — Practitioner attestation

Practitioner credentials and CPSO/CPSA/CPSBC/etc. registration
Attestation of clinical responsibility and follow-up reporting

Submission and review

Submitted by fax (613-941-3194) or via Health Canada SAP portal.
Review timeline historically 1–4 weeks; lengthening through 2025.
Outcome: case-specific authorization (or denial).
Post-treatment Form C report by the practitioner.

Statistics through 2025 — the access landscape

PsyCan (Psychedelics Canada) and TheraPsil have published periodic statistics on Canadian SAP psilocybin approvals. The aggregate picture as of mid-2025:

Year	Approximate psilocybin SAP approvals
2022 (post-amendment year)	~56
2023	~106 (peak year)
2024	~104
2025 (through mid-year)	~35 (significant decline)
Cumulative through mid-2025	~301

Approval rates historically ran around 78% per industry reporting through 2024. PsyCan's September 2025 report on the sharp decline in Health Canada SAP approvals documented a material drop in 2025 monthly approvals and lengthening review timelines, which the trade association and TheraPsil have advocated to address.

The honest 2026 takeaway: the SAP psilocybin pathway is real but materially harder to access than in 2023–2024. Patients pursuing this pathway should plan accordingly.

Drug supply chain — Canadian licensed producers

Health Canada has licensed several Canadian dealers to produce or import psilocybin for SAP-authorized patients:

Filament Health — first DEA-licensed Canadian natural psilocybin producer. Markets the PEX010 capsule (25 mg synthetic psilocybin). Often provides drug at no charge to SAP-approved patients — a meaningful Canadian-specific cost-reduction element.
Optimi Health — synthetic psilocybin producer.
Psyence Group — natural psilocybin supplier.
Compass Pathways COMP360 — UK-based; some Canadian imports for SAP patients on Compass-protocol pathways.

The drug-supply situation has been stable across multiple producers; capacity is adequate to meet current SAP demand.

Constitutional and Federal Court challenges

The Canadian SAP psilocybin landscape has been shaped by ongoing legal advocacy:

Tobin v. Canada (and related work)

Dr. Bruce Tobin, TheraPsil co-founder, has been involved in constitutional challenge work seeking expanded access for psilocybin and MDMA. The case's primary thrust has been Charter-of-Rights-based arguments around access for end-of-life and serious-illness patients.

Toth v. Canada (Federal Court of Appeal, 2025)

A more recent Federal Court of Appeal case addressing practitioner training-pathway exemptions rather than patient access. The FCA ruled that Health Canada's blanket denial of experiential training exemptions to healthcare practitioners was unreasonable, remitting 96 practitioners' applications for redetermination. The case's resolution remains in process at the time of writing; outcomes will affect Canadian psilocybin training capacity.

Section 56(1) class exemptions

Health Canada has continued to issue class exemptions for SAP-authorized activities, providing regulatory clarity for practitioners storing, transporting, and administering psilocybin under SAP authorization. This is a regulatory architectural detail that matters operationally for clinicians.

The future regulatory pathway — what changes with NOC approval

Health Canada Notice of Compliance (NOC) approval for a psilocybin product would transform the access landscape from SAP-only to approved-indication. The most likely earliest pathway:

Compass Pathways COMP360

Compass Pathways has run multiple Phase 2 trials (Goodwin 2022 NEJM Phase 2b N=233 in TRD) and is conducting Phase 3 trials in TRD. If the Phase 3 program succeeds and Compass submits a NOC application, Health Canada review typically takes 1–2 years. A successful NOC would mean:

Compass COMP360 25 mg becomes Health Canada-approved for TRD
Standard prescribing pathway opens (no SAP required for TRD specifically)
Provincial drug formulary listing pathways become possible (CDA-AMC review, INESSS, etc.)
Insurance coverage pathways open (private prior authorization, possibly public coverage)
Clinical training and certification frameworks formalize
Compass Pathways' Janssen Journey-equivalent controlled distribution program would establish

This would be analogous to Spravato's May 2020 Health Canada approval for TRD — a regulatory pathway that converted ketamine-family TRD treatment from off-label to approved-indication for esketamine specifically.

Other possible NOC pathways

Usona Institute (US-based non-profit), Cybin (Canadian-listed company), and other developers are conducting Phase 2 and Phase 3 work that could produce future Canadian NOC submissions.

The honest framing: Health Canada NOC approval would substantially expand Canadian psilocybin access if and when it occurs. The 2026 SAP-pathway-only landscape is a transitional regulatory moment.

How ATMA CENA operates within the current SAP framework

ATMA CENA's role in SAP-pathway psilocybin work:

ATMA CENA does not initiate SAP applications. The medical SAP request is initiated by the patient's prescribing physician or nurse practitioner.
ATMA CENA supports preparation and integration for SAP-authorized patients via the three-phase psychedelic-assisted therapy model.
ATMA CENA's care coordination model lets the patient's existing therapist remain primary while ATMA CENA's clinical infrastructure provides the psychotherapy wraparound around dosing.
ATMA CENA's training program prepares clinicians for psychedelic-assisted therapy work, including foundations applicable to SAP-pathway psilocybin support. See Psychedelic Therapy Training in Canada.

For physicians evaluating SAP applications who want clinical-team coordination, ATMA CENA's clinical team can discuss preparation/integration support and care coordination arrangements.

Frequently asked questions

What is the legal basis for Canadian psilocybin SAP access? Health Canada's January 5, 2022 amendment to the Food and Drug Regulations, which restored practitioner-initiated SAP access for restricted drugs including psilocybin. The amendment repealed 2013 restrictions that had previously excluded restricted drugs from SAP.

Can a patient apply for SAP themselves? No. SAP applications are physician- or nurse-practitioner-initiated. Patients work with a willing prescriber who submits the application on their behalf.

What's the typical review timeline? Historically 1–4 weeks; lengthening through 2025 per PsyCan reporting. Plan for 2–8 weeks or longer in 2026.

Has psilocybin been approved by Health Canada for any indication? No, as of 2026. SAP is the only legal therapeutic pathway. Compass Pathways' Phase 3 program may produce a NOC submission for TRD in coming years.

Where does the drug come from once approved? Health Canada-licensed Canadian producers: Filament Health (often at no charge to SAP patients), Optimi Health, Psyence Group, or imported Compass COMP360.

What's the role of TheraPsil? TheraPsil supports patients in finding willing prescribers, trains Canadian clinicians, advocates for regulatory expansion, and has been involved in constitutional challenge work. Their patient-support function fills a meaningful gap in the SAP pathway.

What conditions are SAP-approved for? End-of-life distress (most common), treatment-resistant depression, alcohol use disorder, demoralization, cluster headache, OCD, anorexia, others case-by-case. Approval depends on documentation, clinical justification, and prescriber willingness.

What about MDMA SAP? MDMA was added to SAP eligibility in the same January 2022 amendment. MDMA-AT for PTSD has been the most common indication. MDMA SAP approvals have been substantially fewer than psilocybin per industry reporting.

Is the SAP pathway tightening? Yes. PsyCan reported a sharp decline in 2025 approvals; review timelines have lengthened. The pathway remains real but materially harder than 2023–2024.

Will psilocybin become formally approved in Canada? Possibly, depending on Phase 3 trial outcomes (Compass Pathways most prominently) and subsequent NOC submissions. Approval would substantially expand access — converting from SAP-only to approved-indication.

Can a nurse practitioner apply for SAP? Yes. The January 2022 amendment authorized both physicians and nurse practitioners to submit SAP requests for psilocybin and MDMA.

What if my SAP application is denied? Options include resubmitting with additional documentation, identifying a different prescriber, or pursuing alternative treatments (e.g., ketamine therapy with broader access, ECT, or other CANMAT-recommended pathways for the indication).

Sources

ATMA CENA — find care near you: https://psychedelic.healthcare/find-care
Health Canada — SAP psychedelic-assisted psychotherapy: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
Health Canada — Special Access Program: https://www.canada.ca/en/health-canada/services/drugs-health-products/special-access/drugs.html
Canada Gazette Part II — January 5, 2022 amendment: https://gazette.gc.ca/rp-pr/p2/2022/2022-01-05/html/sor-dors271-eng.html
Health Canada — Section 56(1) class exemptions: https://www.canada.ca/en/health-canada/services/health-concerns/controlled-substances-precursor-chemicals/policy-regulations/policy-documents/subsection-56-1-class-exemption-practitioners-agents-pharmacists-persons-charge-hospital-hospital-employees-licensed-dealers-conduct-activities-psilocybin-mdma-relation-special-access-program-authorization.html
TheraPsil: https://therapsil.ca/
PsyCan — Sharp decline in SAP approvals (September 2025): https://psychedelicscanada.org/media/2025/09/psycan-discovers-sharp-decline-in-health-canada-approvals-for-doctors-seeking-legal-psychedelic-therapy-for-patients
Filament Health: https://filament.health/
Optimi Health: https://www.optimihealth.ca/
Psyence Group: https://psyence.com/
Goodwin GM, et al. (2022). COMP360 psilocybin in TRD Phase 2b — Phase 3 context. NEJM. https://pubmed.ncbi.nlm.nih.gov/36322843/

Last updated: 2026-05-06

Health Canada SAP for Psilocybin — A Regulatory Deep Dive

Psilocybin access is restricted in many places